title: Different roles of matrix metalloproteinases-2 and -9 after human ischaemic stroke.
abstract: Accumulating data suggest that matrix metalloproteinases (MMPs), in particular MMP-2 and MMP-9, are deleterious after acute ischaemic stroke. A beneficial effect of MMPs in the repairing phases of cerebral ischaemia has also been proposed. This study investigated the relationship between MMP-2 and MMP-9 and stroke subtypes, clinical recovery and haemorrhagic transformation (HT). We measured MMP-9 and MMP-2 plasma levels in 29 patients with ischaemic stroke at days one and seven. MMP-2 levels increased only in lacunar strokes, whilst MMP-9 increased only in patients with more severe stroke. Basal MMP-2 levels were higher in patients with stable or recovering symptoms whilst MMP-9 values at day seven were correlated with worse clinical outcome. No differences related to the presence of HT were found. This study sustains a different behaviour of MMPs after ischaemic stroke. MMP-2 seems to be expressed early and related to better outcome, whilst MMP-9 seems to be late and related to more severe stroke.
authors: Department of Neurological and Psychiatric Sciences, University of Bari, Piazza G. Cesare 12, 1-70124, Bari, Italy.
authors: V
authors: V
authors: Lucivero
authors: M
authors: M
authors: Prontera
authors: D M
authors: DM
authors: Mezzapesa
authors: M
authors: M
authors: Petruzzellis
authors: M
authors: M
authors: Sancilio
authors: A
authors: A
authors: Tinelli
authors: D
authors: D
authors: Di Noia
authors: M
authors: M
authors: Ruggieri
authors: F
authors: F
authors: Federico
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002545:Brain Ischemia / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000097:blood*; D020780:Matrix Metalloproteinase 9 / Q000097:blood*; D008875:Middle Aged; D012189:Retrospective Studies; D018709:Statistics, Nonparametric; D020521:Stroke / Q000097:blood*; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000097:blood
chemical_list: D019715:Tissue Inhibitor of Metalloproteinase-1; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9
references: Stroke. 2001 Dec 1;32(12):2762-7
references: 11739970
references: Eur J Neurosci. 2003 Sep;18(6):1507-17
references: 14511330
references: Stroke. 1993 Jan;24(1):35-41
references: 7678184
references: Free Radic Biol Med. 2005 Jul 1;39(1):71-80
references: 15925279
references: Stroke. 1988 May;19(5):604-7
references: 3363593
references: Eur Neurol. 2006;55(1):11-5
references: 16432302
references: J Cereb Blood Flow Metab. 2003 Dec;23(12):1403-7
references: 14663335
references: Circulation. 2003 Feb 4;107(4):598-603
references: 12566373
references: J Neurosci. 2001 Oct 1;21(19):7724-32
references: 11567062
references: Stroke. 1998 Oct;29(10):2189-95
references: 9756602
references: Circ Res. 2003 May 2;92(8):827-39
references: 12730128
references: Lancet. 1991 Jun 22;337(8756):1521-6
references: 1675378
references: Stroke. 2003 Sep;34(9):2165-70
references: 12907822
references: Stroke. 2005 Jul;36(7):1415-20
references: 15947272
references: Glia. 2002 Sep;39(3):279-91
references: 12203394
references: CNS Drugs. 2001;15(11):819-29
references: 11700147
references: Glia. 2005 Jun;50(4):329-39
references: 15846802
references: Cerebrovasc Dis. 2005;20(3):141-51
references: 16088108
references: Clin Chem Lab Med. 2006;44(4):428-34
references: 16599837
references: Stroke. 1989 Jul;20(7):864-70
references: 2749846
references: Lancet Neurol. 2005 Sep;4(9):530
references: 16136704
references: Neurosci Lett. 1997 Nov 28;238(1-2):53-6
references: 9464653
references: Nat Med. 2006 Apr;12(4):441-5
references: 16565723
references: Stroke. 2003 Jan;34(1):40-6
references: 12511748
references: Stroke. 2001 Aug;32(8):1759-66
references: 11486102